JZYY(SH:600750)2023-03-24 16:00Financial Performance - The company's operating revenue for 2022 was CNY 3,811,641,510.59, representing a 32.63% increase compared to CNY 2,873,974,462.18 in 2021[9] - The net profit attributable to shareholders for 2022 was CNY 596,058,708.67, up 17.87% from CNY 505,687,248.49 in the previous year[9] - The net profit after deducting non-recurring gains and losses was CNY 506,520,866.82, reflecting a 19.42% increase from CNY 424,156,470.17 in 2021[9] - The net cash flow from operating activities for 2022 was CNY 1,015,989,416.27, a 10.79% increase compared to CNY 917,037,660.75 in 2021[9] - The company's total assets at the end of 2022 were CNY 6,243,659,088.84, which is a 4.10% increase from CNY 5,997,600,248.38 at the end of 2021[9] - The basic earnings per share for 2022 was CNY 0.94, representing a 17.50% increase compared to CNY 0.80 in 2021[37] - The diluted earnings per share for 2022 was also CNY 0.94, consistent with the basic earnings per share[37] - The gross profit margin for the main business was 64.93%, an increase of 0.52 percentage points compared to the same period last year[78] Dividends and Shareholder Returns - The proposed cash dividend for 2022 is CNY 6.5 per 10 shares, which would total approximately CNY 40,920.68 million, accounting for 68.65% of the net profit attributable to shareholders[15] - The total cash dividend for 2022, including the distribution from the first three quarters, is estimated to be CNY 72,399.78 million, exceeding 121.46% of the net profit attributable to shareholders[15] - The company maintained a cumulative cash dividend ratio of 50% of the net profit attributable to the parent company since its restructuring listing, emphasizing shareholder returns[62] Operational Highlights - The company completed a share buyback of 33,000 restricted shares in February 2023, which will affect the total number of shares for the dividend distribution[15] - There were no significant risks identified that could materially impact the company's operations during the reporting period[19] - The company achieved operating revenue of 3.812 billion yuan in 2022, a year-on-year increase of 32.63%[45] - The company’s total share capital decreased from 630,000,000 shares at the beginning of the year to 629,581,958 shares at the end of the year due to the cancellation of treasury shares[37] Segment Performance - The non-prescription drug segment generated revenue of 2.618 billion yuan, up 21.31% year-on-year, with core products showing significant growth[52] - The health business reported revenue of 409 million yuan, marking a substantial increase of 66.99% year-on-year[50] - The prescription drug segment saw revenue of 745 million yuan, a remarkable growth of 64.40% year-on-year, largely due to the integration of Haise Pharmaceutical[55] Research and Development - The company introduced 1 generic drug and received 4 supplementary approvals for existing products during the reporting period[56] - The company increased R&D investment and completed 2 special medical products on-site verification during the reporting period[136] - The company’s R&D expenses amounted to CNY 99.97 million, reflecting a year-on-year increase of 13.83%[75] - The company employed 239 R&D personnel, making up 5.9% of the total workforce[102] Market Trends and Challenges - The company anticipates challenges from global economic downturns and ongoing price reductions in generic drugs, necessitating operational innovations[113] - The OTC market is experiencing increased demand due to a shift towards preventive healthcare, with a growing focus on immune enhancement products[114] - The health products market is entering a "golden period" of rapid growth, driven by rising consumer awareness and demand for self-care[117] - The traditional Chinese medicine market is expected to benefit from supportive policies, with a focus on high-quality development and innovation[114] Environmental and Social Responsibility - The group has implemented a wastewater treatment facility with a capacity of 20,000 m³/h, ensuring compliance with discharge standards[166] - The group has adopted natural gas as a clean energy source across all production bases, with emissions of SO2 and nitrogen oxides meeting standards[167] - Jiangzhong Pharmaceutical invested CNY 2.0808 million in social assistance projects, including CNY 1.45 million in funds and CNY 630,800 in material donations[174] - The company has committed to maintaining operational independence and protecting the rights of shareholders, ensuring no misuse of its controlling position[177] Strategic Initiatives - The company is expected to officially launch a new "smart, green, and economical" manufacturing park by the end of 2023[59] - The company has established a robust organizational structure to support its "14th Five-Year Plan" strategy, focusing on talent development and effective execution[61] - The company is actively enhancing its investor relations management tools and improving ESG information disclosure to create a more transparent corporate image[62]